Abstract
About this talk
Cancer therapy continues to face major challenges related to non-specific drug distribution, systemic toxicity, limited drug accumulation within tumor tissues, and the development of therapeutic resistance. Nanomedicine offers an opportunity to address these limitations through the development of nanoscale delivery platforms designed to improve drug transport, stability, controlled release, and interaction with target cells.
Among emerging nanomaterials, carbon nanotubes have attracted increasing attention as potential carriers for anticancer agents because of their distinctive structural properties, high surface area, and capacity for surface functionalization. Functionalization is particularly important because it can improve dispersibility, biocompatibility, drug loading, and interactions with biological targets. These characteristics provide opportunities for developing nanoplatforms capable of carrying therapeutic molecules while supporting more precise delivery strategies.
This work examines the emerging role of carbon nanotube-based nanoplatforms within precision oncology, with particular emphasis on functionalized multi-walled carbon nanotubes for anticancer drug delivery. A focused evaluation of recent scientific literature is used to examine key aspects of nanoplatform development, including surface modification, drug loading, controlled release, cellular uptake, targeting approaches, biocompatibility, and potential therapeutic applications. Carbon nanotube systems are also considered within the broader landscape of contemporary nanocarriers to identify their potential advantages and current limitations.
Current evidence suggests that appropriately functionalized carbon nanotubes may provide versatile platforms for transporting anticancer compounds and may contribute to improved control over drug delivery. However, important challenges remain, particularly regarding toxicity, biodegradation, reproducibility, long-term biological effects, and translation from experimental research to clinical application.
Further investigation and systematic optimization are therefore required before carbon nanotube-based delivery systems can achieve broader therapeutic application. Their continued development may contribute to the evolution of precision nanomedicine by supporting safer, more controlled, and increasingly targeted approaches to anticancer drug delivery.
Speaker
About the speaker
